Researchers led by Nobel Laureate David Baker have harnessed artificial intelligence to design protein binders for intrinsically disordered regions (IDRs), previously considered undruggable targets. Published in Science, these AI-driven approaches enable sequence-based design without requiring structural data, expanding therapeutic options against targets implicated in pain, cancer, and neurological disease. This method represents a notable advance in targeting difficult protein classes, opening new avenues across biomedical research and drug development.